China Oncology ›› 2023, Vol. 33 ›› Issue (6): 566-573.doi: 10.19401/j.cnki.1007-3639.2023.06.003
• Specialists' Commentary • Previous Articles Next Articles
ZHAO Qian(), LING Yunxiao, LIU Guangyu(
)
Received:
2022-12-12
Revised:
2023-05-15
Online:
2023-06-30
Published:
2023-07-26
Share article
CLC Number:
ZHAO Qian, LING Yunxiao, LIU Guangyu. Recent advances and perspectives in the application of repeat sentinel lymph node biopsy in breast cancer patients underwent breast-conserving surgery[J]. China Oncology, 2023, 33(6): 566-573.
Tab.1
Identification rate and axillary recurrence rate of rSLNB in different studies"
Study | Year | Patient number | Identification rate | Axillary recurrence rate | Median follow-up time t/month |
---|---|---|---|---|---|
Haarsma R, et al[ | 2022 | 119 | 79/119 (66.4%) | - | 58.8 |
Yoon C I, et al[ | 2020 | 495 | 356/495 (71.9%) | - | - |
Sávolt Á, et al[ | 2019 | 160 | 106/160 (66.3%) | - | - |
Poodt I G M, et al[ | 2018 | 1 687 | 1 091/1 687 (64.7%) | - | - |
Vugts G, et al[ | 2015 | 536 | 333/536 (62.1%) | - | - |
Intra M, et al[ | 2015 | 212 | 207/212 (97.6%) | 7/212 (3.3%) | 48.0 |
Maaskant-Braat A J, et al[ | 2013 | 692 | 452/692 (65.3%) | - | - |
Cox C E, et al[ | 2008 | 56 | 45/56 (80.4%) | 0/56 (0.0%) | - |
Intra M, et al[ | 2007 | 65 | 63/65 (96.9%) | 0/65 (0.0%) | 45.9 |
Port E R, et al[ | 2007 | 117 | 64/117 (54.7%) | 0/117 (0.0%) | - |
Intra M, et al[ | 2005 | 18 | 18/18 (100.0%) | 0/18 (0.0%) | 12.7 |
[1] |
HALSTED W S. I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894[J]. Ann Surg, 1894, 20(5): 497-555.
doi: 10.1097/00000658-189407000-00075 |
[2] |
FISHER B, ANDERSON S, BRYANT J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16): 1233-1241.
doi: 10.1056/NEJMoa022152 |
[3] |
VERONESI U, CASCINELLI N, MARIANI L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med, 2002, 347(16): 1227-1232.
doi: 10.1056/NEJMoa020989 |
[4] |
BLICHERT-TOFT M, NIELSEN M, DÜRING M, et al. Long-term results of breast conserving surgery vs mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol[J]. Acta Oncol, 2008, 47(4): 672-681.
doi: 10.1080/02841860801971439 |
[5] |
LI Y, LI W W, YUAN L, et al. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?[J]. Cancer, 2022, 128(22): 3919-3928.
doi: 10.1002/cncr.v128.22 |
[6] |
MO C Q, RUAN W H, LIN J Y, et al. Repeat breast-conserving surgery versus salvage mastectomy for ipsilateral breast tumour recurrence after breast-conserving surgery in breast cancer patients: a meta-analysis[J]. Front Oncol, 2021, 11: 734719.
doi: 10.3389/fonc.2021.734719 |
[7] |
QU F L, LIN C J, LIU Z B, et al. Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?[J]. Breast Cancer Res Treat, 2022, 196(1): 97-109.
doi: 10.1007/s10549-022-06708-y |
[8] | HANNOUN-LEVI J M, GAL J, SCHIAPPA R, et al. 10-Year oncological outcome report after second conservative treatment for ipsilateral breast tumor event[J]. Clin Transl Radiat Oncol, 2023, 38: 71-76. |
[9] |
VERONESI U, PAGANELLI G, VIALE G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J]. N Engl J Med, 2003, 349(6): 546-553.
doi: 10.1056/NEJMoa012782 |
[10] |
SCHWARTZ G F, GIULIANO A E, VERONESI U, et al. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania[J]. Cancer, 2002, 94(10): 2542-2551.
pmid: 12173319 |
[11] |
GIULIANO A E, KIRGAN D M, GUENTHER J M, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer[J]. Ann Surg, 1994, 220(3): 391-398; discussion: 398-401.
doi: 10.1097/00000658-199409000-00015 pmid: 8092905 |
[12] |
CAUDLE A S, CUPP J A, KUERER H M. Management of axillary disease[J]. Surg Oncol Clin N Am, 2014, 23(3): 473-486.
doi: 10.1016/j.soc.2014.03.007 pmid: 24882346 |
[13] |
KRAG D N, ANDERSON S J, JULIAN T B, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10): 927-933.
doi: 10.1016/S1470-2045(10)70207-2 pmid: 20863759 |
[14] |
BILIMORIA K Y, BENTREM D J, HANSEN N M, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer[J]. J Clin Oncol, 2009, 27(18): 2946-2953.
doi: 10.1200/JCO.2008.19.5750 pmid: 19364968 |
[15] | YI M, GIORDANO S H, MERIC-BERNSTAM F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database[J]. Ann Surg Oncol, 2010, 17(3): 343-351. |
[16] |
GALIMBERTI V, COLE B F, ZURRIDA S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
doi: 10.1016/S1470-2045(13)70035-4 pmid: 23491275 |
[17] |
GIULIANO A E, HUNT K K, BALLMAN K V, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial[J]. JAMA, 2011, 305(6): 569-575.
doi: 10.1001/jama.2011.90 |
[18] |
GIULIANO A E, MCCALL L, BEITSCH P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J]. Ann Surg, 2010, 252(3): 426-432; discussion 432-433.
doi: 10.1097/SLA.0b013e3181f08f32 pmid: 20739842 |
[19] | ALSUNITAN R I, AL-SAIF A, ALYOUSEF B A, et al. Axillary recurrence in breast cancer patients after negative sentinel lymph node biopsy: retrospective cohort study from Riyadh, Saudi Arabia[J]. Cureus, 2021, 13(12): e20132. |
[20] | KILUK J V, LY Q P, MEADE T, et al. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up[J]. Ann Surg Oncol, 2011, 18(Suppl 3): S339-S342. |
[21] |
POLETTI P, FENAROLI P, MILESI A, et al. Axillary recurrence in sentinel lymph node-negative breast cancer patients[J]. Ann Oncol, 2008, 19(11): 1842-1846.
doi: 10.1093/annonc/mdn393 pmid: 18550574 |
[22] |
KILUK J V, LY Q P, SANTILLAN A A, et al. Erratum to: axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up[J]. Ann Surg Oncol, 2010, 17(2): 552-557.
doi: 10.1245/s10434-009-0800-2 pmid: 19957043 |
[23] |
LYMAN G H, GIULIANO A E, SOMERFIELD M R, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J]. J Clin Oncol, 2005, 23(30): 7703-7720.
doi: 10.1200/JCO.2005.08.001 pmid: 16157938 |
[24] | 郭瑢, 李伦, 张琪, 等. 中国乳腺癌前哨淋巴结活检现状调查研究[J]. 中国癌症杂志, 2020, 30(3): 166-173. |
GUO R, LI L, ZHANG Q, et al. Current status of sentinel lymph node biopsy for breast cancer in China: a cross-sectional study?[J]. China Oncol, 2020, 30(3): 166-173. | |
[25] | ZGAJNAR J, GATZEMEIER W, COSTA A. Will the sentinel lymph node (SLN) stand a second time: SLN biopsy in breast cancer patients with isolated local recurrence following breast conserving therapy and previous SLN procedure[J]. Ann Oncol, 2001, 12(5): 723. |
[26] |
CHUNG M A, CADY B. Caution urged with repeat sentinel lymph node biopsies[J]. Ann Oncol, 2002, 13(12): 1951.
pmid: 12453867 |
[27] |
INTRA M, TRIFIRÒ G, VIALE G, et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy[J]. Ann Surg Oncol, 2005, 12(11): 895-899.
pmid: 16195833 |
[28] |
STELZNER F, FRIEDRICHS N, BÜTTNER R, et al. Lymph vascularity and lymph node metastases on PET and PET/CT: immunohistological and clinical observations[J]. Chirurg, 2005, 76(5): 493-500.
doi: 10.1007/s00104-005-1015-0 |
[29] |
REES W V, ROBINSON D S, HOLMES E C, et al. Altered lymphatic drainage following lymphadenectomy[J]. Cancer, 1980, 45(12): 3045-3049.
pmid: 7388748 |
[30] |
VUGTS G, MAASKANT-BRAAT A J, VOOGD A C, et al. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer[J]. Breast Cancer Res Treat, 2015, 153(3): 549-556.
doi: 10.1007/s10549-015-3571-4 |
[31] |
POODT I G M, VUGTS G, SCHIPPER R J, et al. Repeat sentinel lymph node biopsy for ipsilateral breast tumor recurrence: a systematic review of the results and impact on prognosis[J]. Ann Surg Oncol, 2018, 25(5): 1329-1339.
doi: 10.1245/s10434-018-6358-0 pmid: 29468606 |
[32] |
SÁVOLT Á, CSERNI G, LÁZÁR G, et al. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer[J]. Eur J Surg Oncol, 2019, 45(10): 1835-1838.
doi: S0748-7983(19)30454-8 pmid: 31126680 |
[33] |
KARAM A, STEMPEL M, CODY H S 3rd, et al. Reoperative sentinel lymph node biopsy after previous mastectomy[J]. J Am Coll Surg, 2008, 207(4): 543-548.
doi: 10.1016/j.jamcollsurg.2008.06.139 |
[34] |
COX C E, FURMAN B T, KILUK J V, et al. Use of reoperative sentinel lymph node biopsy in breast cancer patients[J]. J Am Coll Surg, 2008, 207(1): 57-61.
doi: 10.1016/j.jamcollsurg.2008.01.017 |
[35] |
INTRA M, TRIFIRÒ G, GALIMBERTI V, et al. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence[J]. Br J Surg, 2007, 94(10): 1216-1219.
pmid: 17583891 |
[36] |
INTRA M, VIALE G, VILA J, et al. Second axillary sentinel lymph node biopsy for breast tumor recurrence: experience of the European institute of oncology[J]. Ann Surg Oncol, 2015, 22(7): 2372-2377.
doi: 10.1245/s10434-014-4282-5 pmid: 25515197 |
[37] |
MAASKANT-BRAAT A J, VOOGD A C, ROUMEN R M, et al. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature[J]. Breast Cancer Res Treat, 2013, 138(1): 13-20.
doi: 10.1007/s10549-013-2409-1 |
[38] |
HAARSMA R, VAN LOEVEZIJN A A, DONSWIJK M L, et al. Added value of repeat sentinel lymph node biopsy in FDG-PET/CT node-negative patients with ipsilateral breast cancer recurrence[J]. Breast Cancer Res Treat, 2022, 194(3): 617-627.
doi: 10.1007/s10549-022-06654-9 |
[39] |
YOON C I, AHN S G, KIM D, et al. Repeat sentinel lymph node biopsy for ipsilateral breast tumor recurrence after breast conserving surgery with sentinel lymph node biopsy: pooled analysis using data from a systematic review and two institutions[J]. Front Oncol, 2020, 10: 518568.
doi: 10.3389/fonc.2020.518568 |
[40] |
PORT E R, GARCIA-ETIENNE C A, PARK J, et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence[J]. Ann Surg Oncol, 2007, 14(8): 2209-2214.
pmid: 17268882 |
[41] |
SCHRENK P, TAUSCH C, WAYAND W. Lymphatic mapping in patients with primary or recurrent breast cancer following previous axillary surgery[J]. Eur J Surg Oncol, 2008, 34(8): 851-856.
doi: 10.1016/j.ejso.2007.11.006 pmid: 18162358 |
[42] |
MAASKANT-BRAAT A J, ROUMEN R M, VOOGD A C, et al. Sentinel node and recurrent breast cancer (SNARB): results of a nationwide registration study[J]. Ann Surg Oncol, 2013, 20(2): 620-626.
doi: 10.1245/s10434-012-2625-7 |
[43] |
JACKSON B M, KIM S, DAVIDSON R, et al. Repeat operative sentinel lymph node biopsy[J]. Clin Breast Cancer, 2006, 6(6): 530-532.
pmid: 16595037 |
[44] | VUGTS G, MAASKANT-BRAAT A J, VOOGD A C, et al. Improving the success rate of repeat sentinel node biopsy in recurrent breast cancer[J]. Ann Surg Oncol, 2015, 22(suppl 3): S529-S535. |
[45] |
GURU S D, HOSKIN T L, WHALEY D H, et al. Repeat sentinel lymph node surgery in recurrent breast cancer: peritumoral vs periareolar injections[J]. Clin Breast Cancer, 2021, 21(5): 466-476.
doi: 10.1016/j.clbc.2021.02.004 |
[46] |
VICINI E, LEONARDI M C, FONTANA S K R, et al. How to perform repeat sentinel node biopsy safely after a previous mastectomy: technical features and oncologic outcomes[J]. Ann Surg Oncol, 2022, 29(3): 1750-1760.
doi: 10.1245/s10434-021-10986-z |
[47] |
POODT I G M, VUGTS G, MAASKANT-BRAAT A J G, et al. Risk of regional recurrence after negative repeat sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence[J]. Ann Surg Oncol, 2018, 25(5): 1312-1321.
doi: 10.1245/s10434-018-6384-y pmid: 29497910 |
[48] | 中国抗癌协会. 乳腺癌前哨淋巴结活检规范化操作指南(2022精要版)[J]. 中国肿瘤临床, 2022, 49(22): 1135-1142. |
China Anti-Cancer Association. Guidelines for standardized practice of sentinel lymph node biopsy in breast cancer (2022 abridged version)[J]. Chin J Clin Oncol, 2022, 49(22): 1136-1142. | |
[49] |
VOOGD A C, VAN OOST F J, RUTGERS E J, et al. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer[J]. Eur J Cancer, 2005, 41(17): 2637-2644.
pmid: 16115758 |
[50] |
POODT I G M, VUGTS G, SCHIPPER R J, et al. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence[J]. Br J Surg, 2019, 106(5): 574-585.
doi: 10.1002/bjs.11097 pmid: 30908615 |
[51] |
AEBI S, GELBER S, ANDERSON S J, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial[J]. Lancet Oncol, 2014, 15(2): 156-163.
doi: 10.1016/S1470-2045(13)70589-8 pmid: 24439313 |
[52] |
LEE J H, LEE S K, PARK S M, et al. Independent prognostic factors for overall survival after salvage operation for ipsilateral breast tumor recurrence following breast-conserving surgery[J]. J Breast Cancer, 2015, 18(4): 386-393.
doi: 10.4048/jbc.2015.18.4.386 pmid: 26770246 |
[53] |
VOOGD A C, VAN TIENHOVEN G, PETERSE H L, et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch study group on local recurrence after breast conservation (BORST)[J]. Cancer, 1999, 85(2): 437-446.
doi: 10.1002/(sici)1097-0142(19990115)85:2<437::aid-cncr23>3.0.co;2-1 pmid: 10023713 |
[54] |
UGRAS S, MATSEN C, EATON A, et al. Reoperative sentinel lymph node biopsy is feasible for locally recurrent breast cancer, but is it worthwhile?[J]. Ann Surg Oncol, 2016, 23(3): 744-748.
doi: 10.1245/s10434-015-5003-4 pmid: 26644258 |
[55] |
ALPERT T E, KUERER H M, ARTHUR D W, et al. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs salvage breast-conserving surgery and prognostic factors for salvage breast preservation[J]. Int J Radiat Oncol Biol Phys, 2005, 63(3): 845-851.
doi: 10.1016/j.ijrobp.2005.02.035 |
[56] | GROHEUX D, COCHET A, HUMBERT O, et al. 18F-FDG PET/CT for staging and restaging of breast cancer[J]. J Nucl Med, 2016, 57(suppl 1): 17-26. |
[57] |
KRAMMER J, SCHNITZER A, KAISER C G, et al. 18F-FDG PET/CT for initial staging in breast cancer patients-is there a relevant impact on treatment planning compared to conventional staging modalities?[J]. Eur Radiol, 2015, 25(8): 2460-2469.
doi: 10.1007/s00330-015-3630-6 |
[1] | XU Rui, WANG Zehao, WU Jiong. Advances in the role of tumor-associated neutrophils in the development of breast cancer [J]. China Oncology, 2024, 34(9): 881-889. |
[2] | CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong. The progress of treatment for brain metastases of triple-negative breast cancer [J]. China Oncology, 2024, 34(8): 777-784. |
[3] | ZHANG Jian. Clinical consideration of two key questions in assessing menopausal status of female breast cancer patients [J]. China Oncology, 2024, 34(7): 619-627. |
[4] | JIANG Dan, SONG Guoqing, WANG Xiaodan. Study on the mechanism of mitochondrial dysfunction and CPT1A/ERK signal transduction pathway regulating malignant behavior in breast cancer [J]. China Oncology, 2024, 34(7): 650-658. |
[5] | DONG Jianqiao, LI Kunyan, LI Jing, WANG Bin, WANG Yanhong, JIA Hongyan. A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1 [J]. China Oncology, 2024, 34(6): 537-547. |
[6] | HAO Xian, HUANG Jianjun, YANG Wenxiu, LIU Jinting, ZHANG Junhong, LUO Yubei, LI Qing, WANG Dahong, GAO Yuwei, TAN Fuyun, BO Li, ZHENG Yu, WANG Rong, FENG Jianglong, LI Jing, ZHAO Chunhua, DOU Xiaowei. Establishment of primary breast cancer cell line as new model for drug screening and basic research [J]. China Oncology, 2024, 34(6): 561-570. |
[7] | Committee of Breast Cancer Society, China Anti-Cancer Association. Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition) [J]. China Oncology, 2024, 34(3): 316-333. |
[8] | ZHANG Qi, XIU Bingqiu, WU Jiong. Progress of important clinical research of breast cancer in China in 2023 [J]. China Oncology, 2024, 34(2): 135-142. |
[9] | ZHANG Siyuan, JIANG Zefei. Important research progress in clinical practice for advanced breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 143-150. |
[10] | WANG Zhaobu, LI Xing, YU Xinmiao, JIN Feng. Important research progress in clinical practice for early breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 151-160. |
[11] | LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua. Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial [J]. China Oncology, 2024, 34(2): 161-175. |
[12] | CHEN Yuanxiang, YU Tao, YANG Shiyu, ZENG Tao, WEI Lan, ZHANG Yan. KDM4A promotes the migration and invasion of breast cancer cell line MDA-MB-231 by downregulating BMP9 [J]. China Oncology, 2024, 34(2): 176-184. |
[13] | HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190. |
[14] | ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin. “Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer [J]. China Oncology, 2024, 34(11): 1045-1052. |
[15] | OUYANG Fei, WANG Yang, CHEN Yu, PEI Guoqing, WANG Ling, ZHANG Yang, SHI Lei. Construction of the prediction model of breast cancer bone metastasis based on machine learning [J]. China Oncology, 2024, 34(10): 903-914. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd